BridgeBio Oncology Therapeutics Inc Com

Research BridgeBio Oncology Therapeutics Inc Com (BBOT) on Bullrun: market cap USD 613.62M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBBOT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 613.62M
• Financial periodFY2025
• Net income-USD 134.04M
• Free cash flow-USD 114.50M

Valuation Snapshot

latest market cap is USD 613.62M.

About BridgeBio Oncology Therapeutics Inc Com

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer;

Frequently asked questions

What is BridgeBio Oncology Therapeutics Inc Com's market cap?

BridgeBio Oncology Therapeutics Inc Com's market capitalization is USD 613.62M.

What does BridgeBio Oncology Therapeutics Inc Com do?

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.